EGFR and lung cancer: Indeed, among EGFR-mutant lung cancers with acquired resistance to their initial EGFR inhibitor, there is growing evidence that all resistant cells may not share the same, but exhibit different resistance mechanisms, likely reflecting both intratumoural and intertumoural heterogeneity, as well as dynamic changes in the relative populations of resistant clones over time14, 36, 37.